Insulet (PODD) Akcija Kursas
Insulet Kursas
Pajamos augo 41,6 % per metus per pastaruosius 19 metus iki 2,71 mlrd. USD. Pelnas akcijai augo 81,5 % per metus per pastaruosius 7 metus. Insulet grynoji marža dabar yra 9,1 %, išaugo nuo 1,5 % prieš kelerius metus. Analitikų tikslinės kainos mediana yra 180,00 USD, t. y. virš dabartinę kainą 33,6 %. Iš 33 analitikų 20 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Insulet akcijos kaina
Insulet akcija ir akcijų analizė
Dažnai užduodami klausimai apie Insulet akciją
The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.
Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.
The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.
Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.
Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.
Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.
Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.
Analitikai šiuo metu nustato vidutinę Insulet akcijos tikslinę kainą 185,18 USD (mediana: 180,00 USD), t. y. +37,4 % palyginti su paskutine kaina. Konsensusas pagrįstas 33 analitikų reitingais.
33 analitikai šiuo metu vertina Insulet akciją: 20 rekomenduoja pirkti, 13 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Insulet gaus 3,29 mlrd. USD pajamų ir 6,62 USD pelno akcijai.
Pagal dabartinį kursą Insulet akcija kainuoja 120,27 EUR (134,77 USD).
Insulet akcija (PODD) kotiruojama 5 biržose, įskaitant: NASDAQ (PODD), SIX (Zürich) (GOV.SW), Frankfurt (GOV.F), München (GOV.MU), Düsseldorf (GOV.DU).
Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.
tikėtina pelnas Insulet yra 3,29 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Insulet yra 467,51 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Insulet šiuo metu yra 20,37. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Insulet akcijos vertę.
Kainų ir pardavimų santykis (KUV) Insulet šiuo metu yra 2,89. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Insulet akcijos įvertinimo metrika.
Eulerpool kokybės balas Insulet yra 6/10.
Insulet ISIN yra US45784P1012. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Insulet WKN yra A0MQX8. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Insulet prekybos žymė yra PODD. Ši biržos žymė naudojama Insulet akcijoms prekiauti biržoje.
Insulet akcija
Insulet Pagrindiniai konkurentai
Insulet Biržos simbolis
Insulet FIGI
Visos Insulet pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Insulet akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Insulet. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: